Ghent, 14th September 2023.
We are proud to part of the thriving community of life sciences, medtech, and digitech experts within the healthcare cluster of Ghent.
This flourishing ecosystem has been featured in an article in Labiotech, which highlights the seamless cooperation across companies, academic institutions, research centres, and healthcare facilities within Ghent.
Read the whole article here to explore the synergy between biotechnology, medical technology, and digital health in Ghent, a thriving European hub for technological innovation – including the exciting contributions of BioLizard.
If you’d like to learn more about how BioLizard can help you with all your data needs, reach out to us today. Let’s transform your data into actionable insights together!
BioLizard is proud to have received the Best Poster Award at the European Society for Spatial Biology (ESSB) conference, recognising our work on benchmarking cell segmentation methods for single-cell spatial transcriptomics.
Paul Vauterin has transitioned from Chief Technology Officer (CTO) to Chief Operating Officer (COO) at BioLizard, reflecting a shift in focus towards helping organisations integrate AI into their operations and unlock greater value from their data.
For over a century, the life sciences industry has relied on animal models as the standard for predicting drug safety and effect. But today, the industry faces a harsh reality: over 90% of new drugs that appear safe and effective in animal tests ultimately fail in human clinical trials (see for example Ineichen et al. 2024 [1] and Marshall et al. 2023[2])
